Who is sponsoring NCT00419991?

NCT00419991 is sponsored by CPL Associates.

What condition does NCT00419991 study?

NCT00419991 studies Staphylococcal Infections.

What is the status of NCT00419991?

NCT00419991 is currently COMPLETED.

Last reviewed 2011-06-21 · How we verify

An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection

NCT00419991 Phase 4 COMPLETED

Tigecycline is being developed as an agent that overcomes tetracycline-resistance mechanisms and provides activity against emerging multi-drug resistant pathogens. The purpose of this protocol is to determine the linkage between time related clinical measures of infection response and time to bacterial eradication in patients with intravascular catheter infections caused by Staphylococcus epidermidis and other coagulase negative staphylococci.

Details

Lead sponsor	CPL Associates
Phase	Phase 4
Status	COMPLETED
Enrolment	10
Start date	2007-01
Completion	2008-05

Conditions

Staphylococcal Infections

Interventions

Tigecycline

Primary outcomes

Time to bacterial eradication — 7-14 days

Countries

United States